Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02857816 · ClinicalTrials.gov registry record · NA

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

A NA study of Overactive Bladder, sponsored by MedtronicNeuro.

Completed
Registry status
NA
Development phase
154
Enrollment target
11
Study locations

NCT02857816 is a NA study of Overactive Bladder that has completed, run by MedtronicNeuro. The registered enrollment target is 154 participants, below the 208-participant average among 45 other Overactive Bladder trials with a reported enrollment target (26% lower). The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02857816, a NA study of Overactive Bladder, has completed, sponsored by MedtronicNeuro.

COMPLETED
Registry status
NA
Development phase
154 participants
Enrollment target
11
Study locations

Study Summary

To evaluate the NURO system for the treatment of OAB in drug naïve patients.

Conditions Studied

Interventions

  • DEVICE NURO System PTNM Therapy

Study Locations (11)

Florida

  • Pinellas Urology, Inc. - St. Petersburg

Illinois

  • NorthShore University Health System - Evanston

Massachusetts

  • Mount Auburn Hospital - Cambridge

Michigan

  • Advanced Urogynecology of Michigan, P.C. - Dearborn

Minnesota

  • Metro Urology - Woodbury

New Jersey

  • Urology Center Research Institute, LLC - Englewood

New York

  • NYU Urology Associates - New York

North Carolina

  • Alliance Urology Specialists - Greensboro

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2016-09
Est. Completion 2017-11-21
Phase NA

Sponsor

MedtronicNeuro

51 total trials

What the Registry Record Tells You About NCT02857816

The ClinicalTrials.gov registry entry for NCT02857816 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 45 other Overactive Bladder trials with a reported enrollment target (26% lower). The listed sponsor is MedtronicNeuro, which has 51 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which NURO System PTNM Therapy is the first listed.

NCT02857816 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Florida, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02857816 about?

NCT02857816 is a clinical study titled "PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB". To evaluate the NURO system for the treatment of OAB in drug naïve patients.

What is the current status of trial NCT02857816?

This trial is currently completed. It is a NA study. The enrollment target is 154 participants. The study started on 2016-09. Estimated completion is 2017-11-21.

What conditions does trial NCT02857816 study?

This clinical trial studies the following conditions: Overactive Bladder.

What interventions are being tested in trial NCT02857816?

The interventions under investigation include: NURO System PTNM Therapy (DEVICE).

Who is sponsoring clinical trial NCT02857816?

This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02857816 being conducted?

This trial has 11 study locations across Florida, Illinois, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overactive Bladder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.